---
layout: post
title: "Determination That TOPAMAX (Topiramate) Sprinkle Capsules, 50 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
date: 2026-02-05 18:35:39 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-03516
original_published: 2023-02-21 00:00:00 +0000
significance: 8.00
---

# Determination That TOPAMAX (Topiramate) Sprinkle Capsules, 50 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness

**Published:** February 05, 2026 18:35 UTC
**Source:** Federal Register
**Original Published:** February 21, 2023 00:00 UTC
**Document Number:** 2023-03516

## Summary

The Food and Drug Administration (FDA, Agency, or we) has determined that TOPAMAX (topiramate) sprinkle capsules, 50 milligrams (mg), was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for topiramate, sprinkle capsules, 50 mg, if all other legal and regulatory requirements are met.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/02/21/2023-03516/determination-that-topamax-topiramate-sprinkle-capsules-50-milligrams-was-not-withdrawn-from-sale)
- API: https://www.federalregister.gov/api/v1/documents/2023-03516

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
